A 26-Week, Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Response to Treatment (ACR50 [American College of Rheumatology 50% response criteria]) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-Interleukin-1beta Monoclonal Antibody) [canakinumab] Plus MTX [methotrexate] as Compared to MTX Alone in Early Rheumatoid Arthritis Patients.

Trial Profile

A 26-Week, Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Response to Treatment (ACR50 [American College of Rheumatology 50% response criteria]) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-Interleukin-1beta Monoclonal Antibody) [canakinumab] Plus MTX [methotrexate] as Compared to MTX Alone in Early Rheumatoid Arthritis Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Canakinumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Aug 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top